Literature DB >> 20580569

Investigation of the noncovalent interactions between anti-amyloid agents and amyloid beta peptides by ESI-MS.

Eric Martineau1, Janna M de Guzman, Lioudmila Rodionova, Xianqi Kong, Paul M Mayer, Ahmed M Aman.   

Abstract

This paper describes an efficient and reproducible screening method for identifying low molecular weight compounds that bind to amyloid beta peptides (Abeta) peptides using electrospray ionization mass spectrometry (ESI-MS). Low molecular weight compounds capable of interacting with soluble Abeta may be able to modulate/inhibit the Abeta aggregation process and serve as potential disease-modifying agents for AD. The present approach was used to rank the binding affinity of a library of compounds to Abeta1-40 peptide. The results obtained show that low molecular weight compounds bind similarly to Abeta1-42, Abeta1-40, as well as Abeta1-28 peptides and they underline the critical role of Abeta peptide charge motif in binding at physiological pH. Finally, some elements of structure-activity relationship (SAR) involved in the binding affinity of homotaurine to soluble Abeta peptides are discussed. 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20580569     DOI: 10.1016/j.jasms.2010.05.007

Source DB:  PubMed          Journal:  J Am Soc Mass Spectrom        ISSN: 1044-0305            Impact factor:   3.109


  42 in total

Review 1.  Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein.

Authors:  D J Selkoe
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

Review 2.  Alzheimer's disease: the amyloid cascade hypothesis.

Authors:  J A Hardy; G A Higgins
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

3.  Methods for enhancing the accuracy and reproducibility of Congo red and thioflavin T assays.

Authors:  Robyn Eisert; Liseda Felau; Lesley R Brown
Journal:  Anal Biochem       Date:  2006-03-27       Impact factor: 3.365

4.  Method for distinguishing specific from nonspecific protein-ligand complexes in nanoelectrospray ionization mass spectrometry.

Authors:  Jiangxiao Sun; Elena N Kitova; Weijie Wang; John S Klassen
Journal:  Anal Chem       Date:  2006-05-01       Impact factor: 6.986

5.  Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides Abeta40 and Abeta42: stable trimer or tetramer formation by Abeta42.

Authors:  Yun-Ru Chen; Charles G Glabe
Journal:  J Biol Chem       Date:  2006-06-29       Impact factor: 5.157

6.  Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease.

Authors:  Stefan Barghorn; Volker Nimmrich; Andreas Striebinger; Carsten Krantz; Patrick Keller; Bodo Janson; Michael Bahr; Martin Schmidt; Robert S Bitner; John Harlan; Eve Barlow; Ulrich Ebert; Heinz Hillen
Journal:  J Neurochem       Date:  2005-08-31       Impact factor: 5.372

7.  N-truncated amyloid-beta oligomers induce learning impairment and neuronal apoptosis.

Authors:  Ihsen Youssef; Sabrina Florent-Béchard; Catherine Malaplate-Armand; Violette Koziel; Bernard Bihain; Jean-Luc Olivier; Brigitte Leininger-Muller; Badreddine Kriem; Thierry Oster; Thierry Pillot
Journal:  Neurobiol Aging       Date:  2007-04-24       Impact factor: 4.673

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

9.  Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution.

Authors:  H LeVine
Journal:  Protein Sci       Date:  1993-03       Impact factor: 6.725

10.  Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease.

Authors:  R Kisilevsky; L J Lemieux; P E Fraser; X Kong; P G Hultin; W A Szarek
Journal:  Nat Med       Date:  1995-02       Impact factor: 53.440

View more
  6 in total

1.  Clinical Effects of Oral Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification.

Authors:  M N Sabbagh
Journal:  J Prev Alzheimers Dis       Date:  2017

2.  Detection of Amyloid Beta (Aβ) Oligomeric Composition Using Matrix-Assisted Laser Desorption Ionization Mass Spectrometry (MALDI MS).

Authors:  Jasmine S-H Wang; Shawn N Whitehead; Ken K-C Yeung
Journal:  J Am Soc Mass Spectrom       Date:  2018-02-20       Impact factor: 3.109

Review 3.  A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.

Authors:  Eric Karran; John Hardy
Journal:  Ann Neurol       Date:  2014-07-02       Impact factor: 10.422

4.  Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.

Authors:  John A Hey; Jeremy Y Yu; Mark Versavel; Susan Abushakra; Petr Kocis; Aidan Power; Paul L Kaplan; John Amedio; Martin Tolar
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

Review 5.  Structure and Function of Alzheimer's Amyloid βeta Proteins from Monomer to Fibrils: A Mini Review.

Authors:  Nikhil Agrawal; Adam A Skelton
Journal:  Protein J       Date:  2019-08       Impact factor: 2.371

6.  Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer's Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data.

Authors:  Petr Kocis; Martin Tolar; Jeremy Yu; William Sinko; Soumya Ray; Kaj Blennow; Howard Fillit; John A Hey
Journal:  CNS Drugs       Date:  2017-06       Impact factor: 5.749

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.